Alloksys reports interim results of its clinical phase IIb trial with Alkaline Phosphatase therapy RESCAP® in critical care patients
www.alloksys.com Wageningen, the Netherlands, 24 August 2023 – Alloksys Life Sciences, a clinical stage biotech company specializing in the development of critical care medicines, today announced interim results from its APPIRED-III study. The phase IIb trial focused on evaluating the efficacy of RESCAP® (REScuing Alkaline Phosphatase) in 271 patients undergoing cardiothoracic surgery. The results demonstrate […]
RESCAP® IN SEVERE BURN WOUND TRIAL
Alloksys’s RESCAP® platform therapeutic compound will be applied in patients that suffer from severe burn trauma. RESCAP® administration is expected to significantly attenuate the overall ischemic clinical condition of these severely burn-patients and thereby improve on recuperation of these patients, primarily during ICU treatment period. The study will be carried out at the Burn Centre, […]
JANUARY 2020 APPIRED III – 9 INTERNATIONAL CENTRES AND MORE TO COME
APPIRED III study is getting well on its way with 9 centres started with including patients. These centres are Singapore NUH, CZE Eindhoven, Jessa, Hasselt, UniMed Wien Vienna, Almazov Heart Centre St Petersburg and IJN Kuala Lumpur. Recently Monash Melbourne, AZM Middelares, Gent, MUMC Maastricht were added. Four additional centers in St Petersburg and Kazan […]
CLINICAL DATA APPIRED I AND APPIRED II ARE BASIS FOR BREAKTHROUGH
Computational model clarifies immune response during cardiac surgery 11 October 2018 A research team led by Peter Sloot, professor of Complex Adaptive Systems at the UvA, has managed to pinpoint the mechanisms behind the immune response triggered in patients undergoing open heart surgery. The team’s research reveals that by administering supplementary enzymes, so-called alkaline phosphates, […]
UPDATE DECEMBER 2019: SOLID ORGAN TRANSPLANTATION STUDY WELL ON ITS WAY
After approval was obtained in October 2018, the kidney transplantation study with RESCAP® platform technology under supervision of PI Dr Joost van der Heijden from VUmc Amsterdam found its “First Patient In” status in June 2019. Ischemic injury in kidneys to be transplanted are cause of serious complications and limit overall success rate of transplantation. […]
SISTER COMPANY AMRIF READYING UP FOR CLINICAL TRIAL IN CHRONIC INFLAMMATORY DISEASE
AMRIF, Alloksys’s sister company is readying up for trials in several chronic inflammatory disease applications. Among these diseases are unmet medical need applications in Neurodegenerative diseases Parkinson and Alzheimer as well in several complications from diabetes. Protocols, clinicians, clinical centers, specialty institutes and patients have committed to participate in these studies. The studies will start […]
APPIRED III STARTED RECRUITMENT IN ASIA AT NUHCS, SINGAPORE
Following the start of patient inclusion in Europe, the first Asian center participating international study APPIRED lll has started patient recruitment. The National University Heart Centre, Singapore (NUHCS) is the country’s national heart specialty Centre. It is also taking international leadership in this trial, led by principal investigator Professor Theodoros Kofidis MD, PhD. The objective […]
